Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2014 > Volume 23 Number 2 March 2014 > MISCELLANEOUS > Sutureless Perceval Aortic Valve in Comparison with the Stented Carpentier-Edwards Perimount Aortic Valve

Sutureless Perceval Aortic Valve in Comparison with the Stented Carpentier-Edwards Perimount Aortic Valve

Karl Christian König, Thorsten Wahlers, Maximilian Scherner, Jens Wippermann

Klinik für Herz- und Thoraxchirurgie, Herzzentrum, Universitätsklinik Köln, Cologne, Germany

Background and aim of the study: The Sorin Perceval S (SP) sutureless bioprosthesis was developed as an advancement of conventional biological aortic valve replacement (AVR) with stented bioprostheses, and perhaps also as an alternative to the transcatheter aortic valve implantation (TAVI) procedure, especially for high-risk patients. Herein are described the authors’ early results with SP valve replacement, compared to AVR with Carpentier-Edwards Perimount (EP) stented valves.

Methods: Between September 2012 and February 2013, a total of 14 patients was enrolled in a single-center SP study group, and their data were analysed in a prospective manner. For comparison, 14 patients who received an EP valve replacement during the same period were matched with the SP group, in a retrospective manner. Hemodynamic parameters and clinical outcome were monitored until discharge of the patients in order to analyze the early results of the two groups.

Results: The cardiopulmonary bypass (CPB) and aortic cross-clamp (ACC) times needed for AVR with SP valves were significantly shorter than with EP valves. The mean CPB time for SP valve replacement without concomitant procedures was 58.4 ± 11.0 min, compared to 71.8 ± 11.3

min in the EP group (p = 0.015), while the mean ACC times were 37.3 ± 6.8 and 49.1 ± 11.2 min, respectively (p = 0.006). Permanent pacemaker implantation was required in four patients after SP valve replacement, but in only one patient after EP valve replacement (p = 0.326). The mean transprosthetic peak and mean gradients were 24.8 ± 5.2 mmHg and 13.3 ± 3.3 mmHg, respectively, in the SP group, and 19.0 ± 6.5 mmHg and 10.4 ± 3.0 mmHg, respectively, in the EP group (p = 0.024 and p = 0.087). The mean valve size was 23.8 ± 1.3 mm and 23.3 ± 1.5 mm in the SP and EP groups, respectively. The fall in platelet count after SP valve replacement was 180.4 ± 79.4 × 103/μl on the first postoperative day (POD), and 114.1 ± 51.2 × 103/μl with a minimum of 42 × 103/μl and a maximum of 230 × 103/μl at the nadir on POD 2.6 ± 4.0. The mean minimum values at the nadir corresponded to 40% of the initial preoperative value.

Conclusion: The sutureless SP bioprosthesis seems to represent a good alternative to conventional stented bioprostheses, especially in older patients with a high-risk profile, and particularly if concomitant surgical procedures are planned.

The Journal of Heart Valve Disease 2014;23:253-258
Sutureless Perceval Aortic Valve in Comparison with the Stented Carpentier-Edwards Perimount Aortic Valve

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.